iTRAQ-Based Quantitative Proteomic Analysis Identified HSC71 as a Novel Serum Biomarker for Renal Cell Carcinoma

Table 1

Description and comparison of clinical and laboratory characteristics of the study subjects.

Characteristic	Discovery samples by iTRAQ		Validation samples by ELISA
	RCC ()	Control ()	RCC ()	Control ()
Age (years)	54.80 ± 13.32	52.80 ± 9.13	53.10 ± 13.33	55.63 ± 13.98
Gender (male/female)	7/3	7/3	18/12	16/14
BMI	22.86 ± 2.57	22.55 ± 2.55	21.78 ± 2.83	22.16 ± 3.02
Hypertension	4 (40%)	2 (20%)	6 (20%)	4 (13.3%)
Diabetes mellitus	2 (20%)	1 (10%)	5 (16.7%)	3 (10%)
Smoking	3 (30%)	3 (30%)	7 (23.3%)	6 (20%)
Pathological stage
pT1	10 (100%)		16 (53.3%)
pT2			11 (36.7%)
pT3			2 (6.7%)
pT4			1 (3.3%)
M0	10 (100%)		28 (93.3%)
M1			2 (6.7%)
Fuhrman grades
G1-2	10 (100%)		21 (70%)
G3-4			9 (30%)
Histological subtype
Clear-cell	10 (100%)		23 (76.7%)
Papillary			3 (10%)
Chromophobe			4 (13.3%)

Data are expressed as (%), or mean ± SD. RCC: renal cell carcinoma.